(Q43542372)

English

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin

scientific article published in March 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

0 references

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author name string

McNeill SA

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hargreave TB

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Geffriaud-Ricouard C

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Santoni J

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Roehrborn CG

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

language of work or name

0 references

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

57

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

459-465

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. I. Symptoms and urodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The day-to-day variation (test-retest reliability) of residual urine measurement

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of Maximum Detrusor Contraction Power in Relation to Bladder Emptying in Patients with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between detrusor function and residual urine in men undergoing prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Postvoid residual urine in the evaluation of men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Variability of post-void residual urine volume in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of terazosin on urine storage and voiding in the aging male with prostatism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901021-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(00)01021-9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43542372&oldid=2098204478"